Registration Dossier

Administrative data

Link to relevant study record(s)

Description of key information

No toxicokinetic studies are available for this substance. However, information from other in vivo studies are available to assess potential toxicokinetic properties of the substance.

Effects noted in the 28-day repeated dose studies indicate this substance is absorbed via oral exposure as systemic toxicity was observed in the kidneys of the animals at the highest tested concentration. Local effects were seen in the stomach primarily due to the formation of hydrogen fluoride when the substance is hydrolysed. It was clear that when repeated dosing was ceased recovery was observed in the stomach.

The substance is corrosive to skin and local effects were observed in the acute dermal irritation and acute dermal toxicity studies. It does not appear the substance is readily absorbed through the skin as no signs of systemic toxicity were noted in the acute dermal toxicity study.

However, much is known about absorption, distribution and excretion of the potential degradation products in animals and man: expert reviews for HF/F-, lithium salts/Li+ and inorganic phosphates are available, summarising this information. Fluoride is retained in bones and teeth; lithium distribution in the body generally follows that of total body water and human therapeutic administration has not produced evidence of marked bioaccumulation. Phosphate is subject to homeostatic regulation in the body. All of these hydrolysis products are ubiquitous in the environment, at levels which are most unlikely to be significantly affected by release of LiPO2F2 during its intended use. No concerns regarding bioaccumulation are therefore raised.

Key value for chemical safety assessment

Bioaccumulation potential:
low bioaccumulation potential

Additional information